Summary
A group of folate analogs of the 10-deaza-aminopterin series, which were designed on the basis of the results of an intensive biochemical and pharmacokinetic program, have been examined in therapy experiments utilizing a group of murine tumor models. These new analogs were found to be markedly superior to methotrexate against four of five ascites tumors (L1210 leukemia, Sarcoma 180, Ehrlich carcinoma and Tapper carcinosarcoma) and against four of five solid tumors (S180, Tapper carcinosarcoma, E0771 mammary adenocarcinoma, Lewis lung carcinoma, and T241 sarcoma). Analogs alkylated (methyl or ethyl) at the 10 position of 10-deaza-aminopterin were found to be the most effective of the group. These analogs achieved log10 reduction in tumor burden several-fold greater in magnitude than methotrexate against L1210 and S180 ascites tumors and there were also long-term survivors. 10-Deaza-aminopterin itself gave a result intermediate between those obtained with the 10-alkyl derivatives and methotrexate. Against the solid forms of the Tapper tumor some partial regressions were obtained with methotrexate and 10-deaza-aminopterin, but a far greater number, extending over a longer period were obtained with the 10-ethyl derivative of 10-deaza-aminopterin. Against the E0771 tumor, 10-deaza-aminopterin was 2-fold and the ethyl derivative of 10-deaza-aminopterin was >5-fold more effective than methotrexate in retarding tumor growth. Evidence for partial regressions and marked effects against metastatic disease were also obtained in the case of the 10-alkyl derivative. Similar results were also obtained with the T241 sarcoma. For Lewis lung carcinoma the relative potency was about the same but overall antitumor effects were more modest.
Similar content being viewed by others
References
Bertino JR (1979) Toward improved selectivity in cancer chemotherapy. Cancer Res 39:294
Chello PL, Sirotnak FM, Dorick DM, Donsbach RC (1977) Therapeutic relevance of differences in the structural specificity of the transport systems for folate analogs in L1210 tumor cells and in isolated murine intestinal epithelial cells. Cancer Res 37:4297
DeGraw JI, Brown VH, Tagawa K, Kisliuk RL, Gaumont Y, Sirotnak FM (1982) Synthesis and antitumor activity of 10-alkyl, 10-deaza-aminopterin. A convenient synthesis of 10-deaza-aminopterin. J Med Chem 25:1227
Kessel D, Hall TC, Roberts D, Wodinsky I (1965) Uptake as a determinant of methotrexate response in mouse leukemias. Science 150: 752
Kessel D, Hall TC, Roberts D (1968) Modes of uptake of methotrexate by normal and leukemic lymphocytes in vitro and their relationship to drug response. Cancer Res 28:564
Margolis S, Philips FS, Sternberg SS (1971) The cytotoxicity of methotrexate in mouse small intestine in relation to inhibition of folic reductase and of DNA synthesis. Cancer Res 31:2037
Schabel FM (1968) In vivo leukemia cell kill kinetic and “curability” in experimental system. In: The proliferation and spread of neoplastic cells. (Symposium of M. D. Anderson Hospital and Tumor Institute at Houston) Williams & Wilkins, Baltimore, p 379
Sirotnak FM (1980) Correlates of folate analog transport, pharmacokinetic and selective antitumor action. Pharmacol Ther 8:71
Sirotnak FM, Donsbach RC (1973) Differential cell permeability and the basis for selective activity of methotrexate during therapy of the L1210 leukemia. Cancer Res 33:1290
Sirotnak FM, Donsbach RC (1975) Further evidence for a basis of selective activity and relative responsiveness during antifolate therapy of murine tumors. Cancer Res 35:1737
Sirotnak FM, Donsbach RC (1976) Kinetic correlates of methotrexate transport and therapeutic responsiveness in murine tumors. Cancer Res 36:1151
Sirotnak FM, DeGraw JI, Moccio DM, Dorick DM (1978) Antitumor properties of a new folate analog, 10-deaza-aminopterin, in mice. Cancer Treat Rep 62:1047
Sirotnak FM, Chello PC, Brockman RW (1979) Potential for exploitation of transport systems in anticancer drug design. Methods Cancer Res 16:382
Sirotnak FM, Chello PL, DeGraw JI, Piper JR, Montgomery JA (1981) Membrane transport and the molecular basis for selective antitumor action of folate analogs. In: Sartorelli A (ed) Molecular actions and targets for cancer chemotherapeutic agents. Academic Press, New York, p 349
Sirotnak FM, Moccio DM, Goutas LJ, Kelleher LE, Montgomery JA (1982a) Biochemical correlates of responsiveness and collateral sensitivity of some methotrexate resistant murine tumors to the lipophilic antifolate, metoprine. Cancer Res 42:924
Sirotnak FM, DeGraw JI, Chello PL, Moccio DM, Dorick DM (1982b) Biochemical and pharmacologic properties of a new folate analog, 10-deaza-aminopterin, in mice. Cancer Treat Rep 66:351
Sirotnak FM, DeGraw JI, Moccio DM, Samuels LL, Goutas LJ (1983) New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 12: 18–25
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sirotnak, F.M., DeGraw, J.I., Schmid, F.A. et al. New folate analogs of the 10-deaza-aminopterin series. Cancer Chemother. Pharmacol. 12, 26–30 (1984). https://doi.org/10.1007/BF00255904
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00255904